New eye injection shows promise for blinding disease
NCT ID NCT05803785
First seen May 15, 2026 · Last updated Jun 16, 2026 · Updated 8 times
Summary
This early-stage study tests the safety of a new drug called BBC1501, given as an injection into the eye, for people with wet age-related macular degeneration (nAMD). The trial involves 18 adults aged 50 and older who have already received standard treatment. The main goal is to see if the drug is safe and tolerable at different doses.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEOVASCULAR AGE-RELATED MACULAR DEGENERATION are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Benobio Investigational site
NOT_YET_RECRUITINGSydney, New South Wales, 2000, Australia
Contact Email: •••••@•••••
-
Sydney Hospital
RECRUITINGSydney, Australia
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.